Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: Results of a phase II study

European Journal of Cancer

Volumn 42, Issue 14, 2006, Pages 2286-2295

  Bollet, Marc A ^a   Sigal Zafrani, Brigitte ^a   Gambotti, Laetitia ^a   Extra, Jean Marc ^a   Meunier, Martine ^a   Nos, Claude ^a   Dendale, Rémi ^a   Campana, François ^a   Kirova, Youlia M ^a   Diéras, Véronique ^a   Fourquet, Alain ^a   for the Institut Curie Breast Cancer Study Group, ^b  

^a INSTITUT CURIE   (France)

^b NONE

Author keywords

Breast cancer; Concurrent radio chemotherapy; Pathological response; Preoperative chemoradiotherapy

Indexed keywords

BICARBONATE; FLUOROURACIL; HORMONE RECEPTOR; METHYLPREDNISOLONE; NAVELBINE; ONDANSETRON;

ADULT; ALOPECIA; ANEMIA; ARTICLE; AXILLARY LYMPH NODE; BLOOD TOXICITY; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; GAMMA RADIATION; HISTOLOGY; HUMAN; INFECTION; ISCHEMIA; LIVER TOXICITY; LUNG TOXICITY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MITOSIS INDEX; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; MITOSIS; PREOPERATIVE CARE; TREATMENT OUTCOME; VINBLASTINE;

EID: 33748099517     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.03.026     Document Type: Article

References (57)

1. Mauriac L., MacGrogan G., Avril A., et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10 1 (1999) 47-52
2. Broet P., Scholl S.M., de la Rochefordiere A., et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat 58 2 (1999) 151-156
3. Wolmark N., Wang J., Mamounas E., et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30 (2001) 96-102
4. Cleator S.J., Makris A., Ashley S.E., et al. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol 16 2 (2005) 267-272
5. van der Hage J.A., van de Velde C.J., Julien J.P., et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19 22 (2001) 4224-4237
6. Mauri D., Pavlidis N., and Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97 3 (2005) 188-194
7. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 9503 (2005) 2087-2106
8. Whelan T.J., Julian J., Wright J., et al. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 18 6 (2000) 1220-1229
9. Fourquet A., Vilcoq J.R., Zafrani B., et al. Medullary breast carcinoma: the role of radiotherapy as primary treatment. Radiother Oncol 10 1 (1987) 1-6
10. Prosnitz L.R., and Goldenberg I.S. Radiation therapy as primary treatment for early stage carcinoma of the breast. Cancer 35 6 (1975) 1587-1596
11. Calle R., Pilleron J.P., Schlienger P., et al. Conservative management of operable breast cancer: ten years experience at the Foundation Curie. Cancer 42 4 (1978) 2045-2053
12. Nobler M.P., and Venet L. Twelve years' experience with irradiation as the primary treatment for breast cancer. Int J Radiat Oncol Biol Phys 7 1 (1981) 33-42
13. Semiglazov V.F., Topuzov E.E., Bavli J.L., et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 5 7 (1994) 591-595
14. Scholl S.M., Fourquet A., Asselain B., et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A 5 (1994) 645-652
15. Calitchi E., Otmezguine Y., Feuilhade F., et al. External irradiation prior to conservative surgery for breast cancer treatment. Int J Radiat Oncol Biol Phys 21 2 (1991) 325-329
16. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22 1 (2004) 69-76
17. Langendijk J.A., Leemans C.R., Buter J., et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 22 22 (2004) 4604-4612
18. Green J.A., Kirwan J.M., Tierney J.F., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358 9284 (2001) 781-786
19. Cooper J.S., Guo M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281 17 (1999) 1623-1627
20. Formenti S.C., Dunnington G., Uzieli B., et al. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol Biol Phys 39 5 (1997) 1059-1068
21. Formenti S.C., Volm M., Skinner K.A., et al. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol 21 5 (2003) 864-870
22. Dieras V., Extra J.M., Bellissant E., et al. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 14 12 (1996) 3097-3104
23. Zambetti M., Demicheli R., De Candis D., et al. Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients. Breast Cancer Res Treat 44 3 (1997) 255-260
24. Zambelli A., Robustelli della Cuna F.S., Ponchio L., et al. Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 61 3 (2000) 241-247
25. Bonneterre J., Roche H., Monnier A., et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87 11 (2002) 1210-1215
26. Fukuoka K., Arioka H., Iwamoto Y., et al. Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer 34 3 (2001) 451-460
27. Masters G.A., Haraf D.J., Hoffman P.C., et al. Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol 16 6 (1998) 2157-2163
28. Longo D.L., Duffey P.L., DeVita Jr. V.T., et al. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 9 11 (1991) 2042-2051
29. ICRU. Report 50 :Prescribing, recording, and reporting photon beam therapy (1993), International Commission on Radiation Units and Measurements, Washington DC
30. Bear H.D., Anderson S., Brown A., et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21 22 (2003) 4165-4174
31. Vincent-Salomon A., Carton M., Freneaux P., et al. ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy. Eur J Cancer 36 5 (2000) 586-591
32. Vincent-Salomon A., Rousseau A., Jouve M., et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer 40 10 (2004) 1502-1508
33. Sataloff D.M., Mason B.A., Prestipino A.J., et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180 3 (1995) 297-306
34. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 5 (1991) 403-410
35. Vincent-Salomon A., MacGrogan G., Couturier J., et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 42 4 (2003) 337-347
36. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 8 (1998) 2672-2685
37. Mauriac L., Durand M., Avril A., et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2 5 (1991) 347-354
38. Smith I.E., A'Hern R.P., Coombes G.A., et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 15 5 (2004) 751-758
39. Fisher E.R., Wang J., Bryant J., et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95 4 (2002) 681-695
40. Chevallier B., Roche H., Olivier J.P., et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16 3 (1993) 223-228
41. Dieras V., Fumoleau P., Romieu G., et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 22 24 (2004) 4958-4965
42. Calitchi E., Kirova Y.M., Otmezguine Y., et al. Long-term results of neoadjuvant radiation therapy for breast cancer. Int J Cancer 96 4 (2001) 253-259
43. von Minckwitz G., Raab G., Caputo A., et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23 12 (2005) 2676-2685
44. Evans T.R.J., Yellowlees A., Foster E., et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 23 13 (2005) 2988-2995
45. Thomas E., Holmes F.A., Smith T.L., et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 22 12 (2004) 2294-2302
46. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23 16 (2005) 3676-3685
47. Green M.C., Buzdar A.U., Smith T., et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23 25 (2005) 5983-5992
48. Ring A.E., Smith I.E., Ashley S., et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91 12 (2004) 2012-2017
49. Petit T., Wilt M., Velten M., et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40 2 (2004) 205-211
50. Formenti S.C., Spicer D., Skinner K., et al. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 52 2 (2002) 397-405
51. Faneyte I.F., Schrama J.G., Peterse J.L., et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88 3 (2003) 406-412
52. Wang J., Buchholz T.A., Middleton L.P., et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 94 12 (2002) 3107-3114
53. Chang J.C., Wooten E.C., Tsimelzon A., et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23 6 (2005) 1169-1177
54. Pietras R.J., Poen J.C., Gallardo D., et al. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59 6 (1999) 1347-1355
55. Scholl S.M., Pierga J.Y., Asselain B., et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A 12 (1995) 1969-1975
56. Touboul E., Buffat L., Lefranc J.P., et al. Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer. Int J Radiat Oncol Biol Phys 34 5 (1996) 1019-1028
57. Bonadonna G., Valagussa P., Brambilla C., et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16 1 (1998) 93-100